Home / Press Release

Category Archives: Press Release

Feed Subscription

‫جیمن کئیر نے anti-SARS-CoV-2 کو بے اثر کرنے والی اینٹی باڈی JMB2002 کے طبی تجربے کے پہلے مرحلے کا آغاز کردیا

ننچانگ،چین، 21 جنوری،2021 /ژن ہوا-ایشیا نیٹ/  — 15جنوری کے دن چینی فارماسوٹیکل کمپنی جیمن گروپ نے اعلان کیا کہ اس نے anti-SARS-CoV-2 کو بے اثر کرنے والی اینٹی باڈی  (JMB2002) کے طبی تجربے کے پہلےمرحلہ کا آغاز کردیا ہے۔ JMB2002 کی طبی تحقیق جن میں اس دوا کی تیاری اور اس کے مہلک اثرات   پر […]

Read More »

NANO Accelerates Content Delivery by Thirty Times with Solutions from ZephyrTel

Bhutan ISP improves customer experience and looks to the public cloud with long-term strategic partnership  LONDON, Jan. 21, 2021 /PRNewswire/ — ZephyrTel, a provider of public cloud solutions serving global telecommunications operators, has embarked on a strategic partnership with NANO, an Internet Service Provider (ISP) in Bhutan. Having already increased content delivery speeds by up to […]

Read More »

Phoollu, Pakistani farmer with millions of fans, just joined SnackVideo

ISLAMBAD, Jan. 21, 2021 /PRNewswire/ — People can now watch Phoollu’s videos to learn all about what rural life is like in Pakistan in a fun way. Phoollu, a Pakistan farmer known for his country-life videos and comedy style, shares about his daily life to his million viewers on SnackVideo, a new and rising short video […]

Read More »


YOUR TRUSTED RESOURCE FOR REAL-TIME, UNBIASED PMTA STATUS UPDATES Miami, FLA, Jan. 20, 2021 (GLOBE NEWSWIRE) — PMTA Verified releases their Unverified List, uncovering e-liquid and device Brand Owners and Manufacturers who have made statements regarding PMTA Submission(s), but have neglected to provide proof to PMTA Verified in the form of a signed Acceptance Letter from the FDA. It has been […]

Read More »

Jemincare initiates phase I clinical trial of anti-SARS-CoV-2 neutralizing antibody JMB2002

NANCHANG, China, Jan. 20, 2021 /Xinhua-AsiaNet/ — On January 15, Jemincare Group, a Chinese pharmaceutical company, announced that it has initiated the phase I clinical trial of anti-SARS-CoV-2 neutralizing antibody (JMB2002). Preclinical studies of JMB2002 including pharmacology and toxicity were carried out systemically. The drug metabolism, safety and efficacy were well performed. In early studies, […]

Read More »
Scroll To Top